Skip to main content
Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial

Fig. 2

HbA1c lowering efficacy of gliclazide MR (a) at month 6 as stratified by baseline HbA1c and (b) as defined by the achievement of HbA1c ≤ 7.0 and ≤ 6.5% at months 3 and 6. n = 1765 for the “ > 7.0 to ≤ 8.0%” group; n = 2074 for the “ > 8.0 to ≤ 9.0%” group; n = 809 for the “ > 9.0 to  ≤ 10.0%” group and n = 758 for the “ > 10.0%” group. *P < 0.001 for the difference between corresponding baseline and month 6 HbA1c values. HbA1c data are presented as mean (SD)

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us